吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Aug 26 2019

Full Issue

Huge Majorities Of Voters Rank Drug Prices As A Top Concern, But Issue Only Getting Passing Mention At Trump's Rallies

Many of President Donald Trump's supporters at his rallies not only cite drug prices as one of their top concerns -- a trend polling consistently shows to hold true for voters nationally as well -- but don't even realize the president has been vocal about the issue in the past. In other pharmaceutical news: the pricey Duchenne drug and the future of Alzheimer's treatments.

The contrast between the two Trump rallies was striking: At one event here in the first primary state in 2016, President Trump railed against the pharmaceutical industry for more than two full minutes 鈥 an eternity for one topic in a campaign speech.聽Forcefully vowing to reject their donations and pledging to empower Medicare to negotiate lower drug prices to save both voters and the federal government billions, Trump declared:聽鈥淲e鈥檙e going to save so much money and those drug companies are going to hate me so much.鈥澛(Florko, 8/23)

Deb and Shawn Jenssen were used to frustration. Their kids had been turned away from studies. Doctors had questioned if they could really be showing signs of a disease even as it made it harder for them to walk. All of it helped explain why that brief moment in an Orlando hotel conference room caught their attention 鈥 why it felt like hope. (Joseph, 8/26)

It鈥檚 been just over a month since Amgen and Novartis ended two studies of an experimental Alzheimer鈥檚 treatment early, the latest in a long string of failures in Alzheimer鈥檚 drug development. There is still no effective treatment for the disease. But as the population ages, the already significant need for an Alzheimer鈥檚 treatment is only growing more urgent, said Dr. David Reese, executive vice president of research and development at Amgen. (Thielking, 8/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, August 7
  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF